MCID: MXD012
MIFTS: 20

Mixed Oligodendroglioma-Astrocytoma

Categories: Cancer diseases

Aliases & Classifications for Mixed Oligodendroglioma-Astrocytoma

MalaCards integrated aliases for Mixed Oligodendroglioma-Astrocytoma:

Name: Mixed Oligodendroglioma-Astrocytoma 12 15 73
Who Grade Ii Mixed Glioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7912
MeSH 44 D009837
NCIt 50 C4050
SNOMED-CT 68 22217002
UMLS 73 C0280793

Summaries for Mixed Oligodendroglioma-Astrocytoma

MalaCards based summary : Mixed Oligodendroglioma-Astrocytoma, also known as who grade ii mixed glioma, is related to oligoastrocytoma and astrocytoma, and has symptoms including headache and seizures. An important gene associated with Mixed Oligodendroglioma-Astrocytoma is TP53 (Tumor Protein P53). The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow.

Related Diseases for Mixed Oligodendroglioma-Astrocytoma

Diseases related to Mixed Oligodendroglioma-Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 11.3
2 astrocytoma 10.0
3 oligodendroglioma 10.0

Symptoms & Phenotypes for Mixed Oligodendroglioma-Astrocytoma

UMLS symptoms related to Mixed Oligodendroglioma-Astrocytoma:


headache, seizures

Drugs & Therapeutics for Mixed Oligodendroglioma-Astrocytoma

Drugs for Mixed Oligodendroglioma-Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
6
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10 tannic acid Approved, Nutraceutical Phase 3
11 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Dermatologic Agents Phase 3,Phase 1,Phase 2
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
14 interferons Phase 3,Phase 1,Early Phase 1
15 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1,Not Applicable
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiviral Agents Phase 3,Phase 1,Early Phase 1
18 Interferon-alpha Phase 3
19 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
20
Histamine Phosphate Phase 3 51-74-1 65513
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Histamine Antagonists Phase 3
24 Histamine H1 Antagonists Phase 3
25 Anti-Allergic Agents Phase 3
26 Antipruritics Phase 3
27
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
28
Iodine Approved, Investigational Phase 2 7553-56-2 807
29
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
32
Hydroxyurea Approved Phase 2 127-07-1 3657
33
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
34
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
38
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
39
Nintedanib Approved Phase 2 656247-17-5 56843413
40
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
41
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
42
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
43
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
44
Mannitol Approved, Investigational Phase 1, Phase 2,Phase 2 69-65-8 453 6251
45
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
46
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
47
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
48
Dopamine Approved Phase 2,Not Applicable 51-61-6, 62-31-7 681
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
50
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
4 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
5 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
6 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
9 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
10 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
11 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
12 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
13 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
14 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
15 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
16 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
17 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
18 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
19 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma Completed NCT00041587 Phase 1, Phase 2 IL13-PE38QQR
20 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Completed NCT00024570 Phase 1, Phase 2 IL13-PE38QQR
21 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
22 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
23 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
24 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
25 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
26 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
27 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
28 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Recruiting NCT02530320 Phase 2 Palbociclib
29 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
30 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
31 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
32 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
33 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2 Temozolomide
34 A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas Recruiting NCT01986348 Phase 2 Selinexor
35 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
36 A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas Active, not recruiting NCT02104310 Phase 2 Fluorine-18-L-dihydroxyphenylalanine
37 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
38 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
39 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
40 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
43 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Terminated NCT00062504 Phase 2 Talampanel
44 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors Terminated NCT00848523 Phase 2 Panobinostat
45 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
46 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn NCT02977689 Phase 2 IDH305
47 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Withdrawn NCT02369367 Phase 2 Irinotecan;Lenalidomide
48 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
49 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
50 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation

Search NIH Clinical Center for Mixed Oligodendroglioma-Astrocytoma

Genetic Tests for Mixed Oligodendroglioma-Astrocytoma

Anatomical Context for Mixed Oligodendroglioma-Astrocytoma

MalaCards organs/tissues related to Mixed Oligodendroglioma-Astrocytoma:

41
Brain, Bone, Bone Marrow

Publications for Mixed Oligodendroglioma-Astrocytoma

Articles related to Mixed Oligodendroglioma-Astrocytoma:

# Title Authors Year
1
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. ( 1564535 )
1992

Variations for Mixed Oligodendroglioma-Astrocytoma

Expression for Mixed Oligodendroglioma-Astrocytoma

Search GEO for disease gene expression data for Mixed Oligodendroglioma-Astrocytoma.

Pathways for Mixed Oligodendroglioma-Astrocytoma

GO Terms for Mixed Oligodendroglioma-Astrocytoma

Sources for Mixed Oligodendroglioma-Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....